Argenx stock gains on bullish analyst targets and solid growth outlook

Published on 09/21/2026 at 12:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock has risen about 30% over the past 12 months as of September 20, 2026, while Wells Fargo and UBS see more than 40% upside over the next year. Recent revenue growth and analyst targets highlight the biotech’s expanding autoimmune portfolio.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx stock (ISIN NL0010832176) has delivered a gain of roughly 30% over the past 12 months as of September 20, 2026, underscoring strong investor confidence in the biotech’s autoimmune drug portfolio, according to The Motley Fool on September 20, 2026. As that analysis notes, the consensus one-year price target implies around 20% upside from current levels, while some top Wall Street analysts expect significantly more.

Analysts see more than 40% upside

According to The Motley Fool on September 20, 2026, Wells Fargo analyst Derek Archila and UBS analyst Xian Deng both assign 12-month price targets for Argenx that are more than 40% above the prevailing share price. In that report, the site highlights that the consensus one-year price target suggests approximately 20% upside, while these two analysts project that Argenx shares could gain over 40% within the next 12 months.

Data compiled by Yahoo Finance as of mid September 2026 show an average analyst price target of around USD 1,180.61 for Argenx, compared with a prevailing share price reported there of roughly USD 990.32. This implies potential upside of close to 20% from that reference level, in line with the wider consensus view described by The Motley Fool.

Consensus and individual targets compared

The same Yahoo Finance overview lists a low price target of USD 900.00 and a high target of USD 1,450.00, framing the range of expectations for Argenx shares among covering analysts. Within that range, the average target of about USD 1,180.61 stands approximately USD 190 above the USD 990.32 reference price cited in the overview, underscoring the roughly 20% gap that analysts see between the current price and their central valuation.

Within this consensus, the latest rating action captured by Yahoo Finance shows Wedbush reaffirming an Outperform rating on Argenx on September 8, 2026, with a price target of USD 1,150.00. That target sits modestly below the average of USD 1,180.61 but still roughly USD 160 above the USD 990.32 reference price, translating into expected upside of around 16% in that particular case.

Stock performance and market positioning

According to Yahoo Finance on September 20, 2026, Argenx shares have risen by roughly 30% over the preceding 12 months. This places the stock ahead of many broader market benchmarks over the same period and provides context for why analysts still see room for additional gains despite the strong run.

The same article notes that the consensus one-year price target implies around 20% further upside from current levels, so even after a 30% increase over the last year, analysts collectively anticipate that Argenx can continue to outperform. For investors, that combination of proven past performance and still significant expected upside is a key part of the story.

Closing stock snapshot

Per data summarized around mid September 2026 on major financial portals for the Nasdaq listing under the ticker ARGX, Argenx stock most recently closed at approximately USD 990.32 on its primary exchange in the United States. At that closing level, and using the average analyst target of about USD 1,180.61 from Yahoo Finance, the shares trade roughly USD 190, or close to 20%, below the consensus one-year price objective as of that date.